Cytotherapy

Papers
(The H4-Index of Cytotherapy is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Editorial Board98
ESTABLISHING A NATIONAL REGULATORY POLICY AND FRAMEWORK FOR THERAPEUTIC USE OF CELL AND TISSUE THERAPIES IN SULTANATE OF OMAN.54
FAPĪ±-TARGETED IMMUNOTHERAPY WITH SIBROTUZUMAB AND HIGH AFFINITY FC-RECEPTOR EXPRESSING NK92 CELLS: A PROMISING APPROACH TO REVERSE FIBROSIS53
CLINICALLY COMPLIANT MATRIX FOR HUMAN ES AND IPSC CULTURE FOR PRECLINICAL AND CLINICAL THERAPY41
OPTIMIZATION OF AUTOMATED SELECTION AND LENTIVIRAL VECTOR MEDIATED TRANSDUCTION OF MSC40
MICROPOROUS PARTICLE SCAFFOLDS FOR MESENCHYMAL STROMAL CELL EXPANSION AND ENHANCED IMMUNOMODULATORY FUNCTION39
ANALYSIS OF COLD CHAIN PROCESSES FOR INVESTIGATIONAL CELL THERAPY PRODUCT SHIPMENTS AND TRANSPORT BASED ON REAL-WORLD TEMPERATURE DATA37
CARTAR WEB TOOL: A CASE STUDY UNVEILING PROMISING TARGETS FOR CHIMERIC ANTIGEN RECEPTOR THERAPIES IN COLORECTAL ADENOCARCINOMA36
Aims and Scope36
SAMPLE TYPE, BUT NOT STORAGE DURATION, IMPACTS POST-THAW CD34 VIABILITY ON CORD BLOOD UNITS35
INVESTIGATING THE INTERPLAY BETWEEN GUT MICROBIOME, MONOCYTES/MACROPHAGES, AND OSTEOARTHRITIS32
COMPARATIVE PROFILING OF MESENCHYMAL STEM CELL EXTRACELLULAR VESICLES FOR APPLICATION IN REGENERATIVE DERMATOLOGY32
EFFECTS OF STORAGE TEMPERATURE ON VITAL PARAMETERS OF CLINICAL GRADE CRYOPRESERVED MESENCHYMAL STEM CELL FINAL PRODUCT32
ECTOPIC EXPRESSION OF CD39, A KEY REGULATOR OF THE PURINERGIC SIGNALING PATHWAY, INCREASED THE IMMUNOMODULATORY PROPERTIES OF MSC-DERIVED EXTRACELLULAR VESICLES31
INTER-DONOR VARIABILITY AND CELLULAR PROLIFERATION: THEIR IMPACT ON THE IMMUNOMODULATORY STRENGTH OF ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN T CELL-MEDIATED HEPATITIS31
SAFETY AND EFFICACY RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF OCU400 MODIFIER GENE THERAPY FOR TREATMENT OF RETINITIS PIGMENTOSA29
Clinical trial assessing the safety and efficacy of human bone marrow-derived allogeneic mesenchymal stem cell therapy for chronic active antibody-mediated rejection in kidney transplant recipients28
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy28
International Society for Cell & Gene Therapy Expanded Access Working Group position paper: key considerations to support equitable and ethical expanded access to investigational cell- and gene-ba28
Distinct effects of intravenous bone marrow-derived mesenchymal stem cell therapy on ischemic and non-ischemic lungs after ischemia-reperfusion injury27
Mesenchymal Stem/Stromal Cells: CELLULAR AGING SECRETES: A COMPARISON OF BONE MARROW DERIVED AND INDUCED MESENCHYMAL STEM CELLS AND THEIR SECRETOME OVER LONG TERM CULTURE27
Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity27
Repeated intravenous doses of human umbilical cord-derived mesenchymal stromal cells for bronchopulmonary dysplasia: results of a phase 1 clinical trial with 2-year follow-up27
Impact of Age and acute GVHD on Thymic Reconstitution Post-HCT: Insights from Multicenter Immune Monitoring of Pediatric and Young Adult Patients26
Programmed spontaneously beating cardiomyocytes in regenerative cardiology26
Editorial Board26
0.23820114135742